On March 31, 2025, the FDA’s Opioid Analgesic REMS mandate took effect, requiring every manufacturer of extended-release and long-acting opioid analgesics to provide prepaid, preaddressed mail-back envelopes with each dispensed prescription. The goal is straightforward: make it easier for patients to dispose of unused opioids safely.
The intention is sound. The execution faces fundamental challenges — challenges that healthcare institutions, reverse distributors, and compliance professionals need to understand. Read More >
